Skip to content

CANNABIS e MALATTIE CRONICHE

L’esperienza dei pazienti ha riconosciuto nella cannabis terapeutica un aiuto molto importante in tutte quelle patologie croniche che non rispondono efficacemente alle terapie convenzionali. Esse sono tante, così come gli studi a supporto .Tra le problematiche cliniche che beneficiano dell’impiego dei derivati della cannabis troviamo tante condizioni che quando sono presenti cronicamente interferiscono in maniera drammatica sulla qualità della vita di chi ne soffre.

La cannabis ad es. è in grado di regolare l’appetito e migliorare la gestione del peso nei disturbi della nutrizione in cui sono presenti inappetenza , nausea e vomito, che possono portare alla cachessia e peggiorare il quadro clinico dei pazienti neoplastici, in terapia con chemio e radio o nei pazienti con AIDS e nell’anoressia nervosa[1]  [2] 

Ha dimostrato il suo potenziale nelle malattie croniche intestinali, caratterizzate da dolori severi, disturbi dell’alvo e malassorbimento come IBS e Crohn e in alcune forme di ulcere gastriche [3 ]  [4] [5]

E’ in grado di controllare tutti i tipi do dolore severo non responsivo agli oppioide , come il dolore neoplastico, il dolore muscolare di tipo spastico e quello da lesioni del midollo spinale;  nella fibromialgia e nella neuropatia diabetica , caratterizzate da dolori in cui antinfiammatori, cortisonici e oppioidi sono insufficienti.[3] [5] [6];

E’ utilizzata con buoni risultati nei tic motori e verbali caratteristici della Sindrome di La Tourette e apporta beneficio in tutte le patologie neurodegenerative come Sclerosi Multipla , SLA, Alzheimer, Morbo di Parkinson e di Huntington.[7][8][9]; epilessia severa non responsiva ai farmaci [10][11][12]; esiti di ictus [13][14];

dolore osseo tipico dell’osteoporosi dove favorirebbe anche la guarigione dalle fratture , grazie alle proprietà che il CBD sembra avere sullo stimolo della sintesi del collagene.[15][16][17];

problematiche oculari cronico-degenerative come degenerazione maculare , retinite diabetica, uveoretinite. e glaucoma [18]; patologie dermatologiche cronico ereditarie di difficile gestione come psoriasi e dermatite atopica [19][21][22]; diabete, obesità [23][24][25][26][27][28][29][30][31][32][33]; disturbi del sonno , ansia, depressione , disturbo da stress post traumatico.[34][35][36][37][38][39][40]

LETTERATURA

[1]  Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic Literature Review.
Oncology Nursing Forum, 36(3), 345-352. doi:10.1188/09.onf.345-352

[2]  Established and Emerging Concepts of Cannabinoid Action on Food Intake and their Potential Application to the Treatment of Anorexia and Cachexia In Handbook of cannabis: Edited by Roger G. Pertwee.
New York: Oxford University Press. Pertwee, R. G., Cristino, L., & Di Marzo, V. (2014).

[3 ]  Uranga JA, Vera G, Abalo R.
Cannabinoid pharmacology and therapy in gut disorders. Biochem Pharmacol. 2018 Nov;157:134-147

 [4] Lahat, A., Lang, A., & Ben-Horin, S. (2012).
Impact of Cannabis Treatment on the Quality of Life, Weight and Clinical Disease Activity in Inflammatory Bowel Disease Patients: A Pilot Prospective Study.
Digestion, 85(1), 1-8. doi:10.1159/000332079  

[5] Rivas-V, J., & García, R. (1980).
Inhibition of histamine-stimulated gastric acid secretion by Δ9-tetrahydrocannabinol in rat isolated stomach.
European Journal of Pharmacology, 65(2-3), 317-318. doi:10.1016/0014-2999(80)90410-0

[3] Pertwee, R. G., Costa, B., & Comelli, F. (2014).
Pain, In Handbook of cannabis: Edited by Roger G. Pertwee.
New York: Oxford University Press.

[5] Toth, C. C., Jedrzejewski, N. M., Ellis, C. L., & Frey, W. H. (2010).
Cannabinoid-Mediated Modulation of Neuropathic Pain and Microglial Accumulation in a Model of Murine Type I Diabetic Peripheral Neuropathic Pain.
Molecular Pain, 6, 1744-8069-6-16. doi:10.1186/1744-8069-6-16

[6] Welch, S. P., & Stevens, D. L. (1992).
Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.
Journal of Pharmacology and Experimental Therapeutics, 262(1), 10-18.

[7] J. Geldenhuys, W., & J. Van der Schyf, C. (2013).
Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases.
Current Medicinal Chemistry, 20(13), 1662-1672. doi:10.2174/09298673113209990112

[8]Fernandèz-Ruiz, J., De Lago, E., Gomez-Ruiz, M., Garcia, C., Sagredo, O., & Garcia-Arencibia, M. (2014).
Neurodegenerative disorders other than Multiple Sclerosis. In Handbook of cannabis: Edited by Roger G. Pertwee.
New York: Oxford University Press

[9]Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity.
Current Drug Targets-CNS & Neurological Disorders. 2005 Dec 1;4(6):677-84.

Nell’ Epilessia severa dei pazienti non responsivi ai farmaci

[10] Pertwee, R. G., Williams, C. M., Jones, N. A., & Whalley, B. J. (2014).
Cannabis and Epilepsy. In Handbook of cannabis: Edited by Roger G. Pertwee.
New York: Oxford University Press

[11] Devinsky, Orrin, et al.
“Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome.”
New England Journal of Medicine 378.20 (2018): 1888-1897.

[12] Tzadok, M., Uliel-Siboni, S., Linder, I., Kramer, U., Epstein, O., Menascu, S., Ben-Zeev, B. (2016).
CBD-enriched medical cannabis for intractable pediatric epilepsy.

[13] Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Lotan, C. (2007).
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury.
American Journal of Physiology-Heart and Circulatory Physiology, 293(6), H3602-H3607. doi:10.1152/ajpheart.00098.2007

[14] Walsh, S. K., Hepburn, C. Y., Kane, K. A., & Wainwright, C. L. (2010).
Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.
British Journal of Pharmacology, 160(5), 1234-1242. [15] Raphael B, Gabet Y.
The skeletal endocannabinoid system: clinical and experimental insights. Journal of basic and clinical physiology and pharmacology. 2016 May 1;27(3):237-45.

[16] Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts.
J Bone Miner Res. 2015 Oct;30(10):1905-13.

[17] Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., … Bab, I. (2006).

Peripheral cannabinoid receptor, CB2, regulates bone mass.
Proceedings of the National Academy of Sciences, 103(3), 696-701. doi:10.1073/pnas.0504187103

[18] Ocular Effects of Topical Administration of 9-Tetrahydrocannabinol in Man.
Archives of Ophthalmology, 100(2), 265-267. doi:10.1001/archopht.1982.01030030267006

[19] Pertwee, R. G., Oddi, S., & Maccarone, M. (2014).
Phytocannabinoids & Skin Disorders. In Handbook of cannabis: Edited by Roger G. Pertwee.
New York: Oxford University Press.

[20] Paradisi, A., Pasquariello, N., Barcaroli, D., & Maccarrone, M. (2007).
Anandamide Regulates Keratinocyte Differentiation by Inducing DNA Methylation in a CB1 Receptor-dependent Manner.
Journal of Biological Chemistry, 283(10), 6005-6012. doi:10.1074/jbc.m707964200

[21] Blázquez, C., Carracedo, A., Barrado, L., Real, P. J., Fernández-Luna, J. L., Velasco, G., Guzmán, M. (2006).
Cannabinoid receptors as novel targets for the treatment of melanoma.
The FASEB Journal, 20(14), 2633-2635. doi:10.1096/fj.06-6638fje

[22] Cerrato, S., Brazis, P., Della Valle, M., Miolo, A., & Puigdemont, A. (2010).
Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFα release from canine skin mast cells.
Veterinary Immunology and Immunopathology, 133(1), 9-15. doi:10.1016/j.vetimm.2009.06.01

[23] Horváth, B., Mukhopadhyay, P., Haskó, G., & Pacher, P. (2012).
The Endocannabinoid System and Plant-Derived Cannabinoids in Diabetes and Diabetic Complications.
The American Journal of Pathology, 180(2), 432-442. doi:10.1016/j.ajpath.2011.11.003

[24] Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2008).
Cannabidiol arrests onset of autoimmune diabetes in NOD mice.
Neuropharmacology, 54(1), 244-249. doi:10.1016/j.neuropharm.2007.06.029

[25] Riedel, G., Fadda, P., McKillop-Smith, S., Pertwee, R. G., Platt, B., & Robinson, L. (2009).
Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice.
British Journal of Pharmacology, 156(7), 1154-1166.

[26] Wargent, E. T., Zaibi, M. S., Silvestri, C., Hislop, D. C., Stocker, C. J., Stott, C. G., … Cawthorne, M. A. (2013).
The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.
Nutrition & Diabetes, 3(5), e68-e68. doi:10.1038/nutd.2013.9

[27] Li, X., Kaminski, N. E., & Fischer, L. J. (2001).
Examination of the immunosuppressive effect of Δ9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes.
International Immunopharmacology, 1(4), 699-712. doi:10.1016/s1567-5769(01)00003-0

[28] Coskun, Z. M., & Bolkent, S. (2014).
Biochemical and immunohistochemical changes in delta-9-tetrahydrocannabinol-treated type 2 diabetic rats.
Acta Histochemica, 116(1), 112-116. doi:10.1016/j.acthis.2013.05.013

[29] Wong, A., Gunasekaran, N., Hancock, D., Denyer, G., Meng, L., Radford, J.Arnold, J. (2011).
The Major Plant-derived Cannabinoid Δ9-Tetrahydrocannabinol Promotes Hypertrophy and Macrophage Infiltration in Adipose Tissue.
Hormone and Metabolic Research, 44(02), 105-113. doi:10.1055/s-0031-1297940

[30] Hollister, L. E., & Reaven, G. M. (1974).
Delta-9-tetrahydrocannabinol and glucose tolerance.
Clinical Pharmacology & Therapeutics, 16(2), 297-302. doi:10.1002/cpt1974162297

[31] Le Foll, B., Trigo, J. M., Sharkey, K. A., & Strat, Y. L. (2013).
Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?.
Medical Hypotheses, 80(5), 564-567. doi:10.1016/j.mehy.2013.01.019

[32] Rajavashisth, T. B., Shaheen, M., Norris, K. C., Pan, D., Sinha, S. K., Ortega, J., & Friedman, T. C. (2012).
Decreased prevalence of diabetes in marijuana users: cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) III.
BMJ Open, 2(1), e000494. doi:10.1136/bmjopen-2011-000494

[33] Levendal R, Schumann D, Donath M, Frost C.
Cannabis exposure associated with weight reduction and b -cell protection in an obese rat model.Phytomedicine. (2012) ;19:575-582.

[34] Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007).
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
The Lancet, 370(9584), 319-328. doi:10.1016/s0140-6736(07)61162-3

[35] Morgan, C. J., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T. P., Curran, H. V. (2011).
Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
Psychological Medicine, 42(02), 391-400. doi:10.1017/s0033291711001322

[36] Degenhardt, L., Coffey, C., Romaniuk, H., Swift, W., Carlin, J. B., Hall, W. D., & Patton, G. C. (2012).
The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood.
Addiction, 108(1), 124-133.

[37] Lutz, B. (2007).
The endocannabinoid system and extinction learning.
Molecular Neurobiology, 36, 92-101.

[38] Marsicano, G., Wotjak, C.T., Azad, S.C., et al. (2002).
The endogenous cannabinoid system controls extinction of aversive memories.
Nature, 418, 530-534.

[39] Pamplona, F.A., Bitencourt, R.M., and Takahashi, R.N. (2008).
Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats.
Neurobiology of Learning and Memory, 90, 290-29

[40] Lin, H.C., Mao, S.C., Su, C.L. and Gean, P.W. (2009).
The role of prefrontal cortex CB1 receptors in the modulation of fear memory